Author(s): Weinreb N, Taylor J, Cox T, Yee J, vom Dahl S
Abstract Share this page
Abstract To assess the extent to which patients with type 1 Gaucher disease (GD1) receiving individualized enzyme replacement therapy with imiglucerase attain six defined therapeutic goals. One hundred and ninety-five GD1 patients enrolled in the ICGG Gaucher Registry, all of whom had data available for hemoglobin, platelet count, liver volume, spleen volume, bone pain, and bone crises at first infusion and after 4 years of therapy with imiglucerase, were evaluated for achievement of published therapeutic goals. The proportion of patients who met all six therapeutic goals increased from 2.1\% at first infusion to 41.5\% at 4 years; > or =5 goals from 12.8\% to 76.9\%; > or =4 goals from 37.4\% to 92.8\%; > or =3 goals from 70.8\% to 99.0\%; and > or =2 goals from 95.4\% to 99.5\%. All patients met at least one goal at first infusion and after 4 years of treatment. The proportion of patients meeting specific therapeutic goals increased for all parameters between first infusion and 4 years of therapy: platelet count (24.6\%-79.5\%), spleen volume (25.6\%-78.5\%), liver volume (45.6\%-90.8\%), bone pain (62.6-70.3\%), hemoglobin (68.2-91.8\%), and bone crises (91.8-99.0\%). On average, patients who received higher doses of imiglucerase achieved a greater number of therapeutic goals. This analysis provides a benchmark for evaluating the utility of a disease management approach for GD1 based on monitoring achievement of therapeutic goals after treatment with imiglucerase. Copyright 2008 Wiley-Liss, Inc.
This article was published in Am J Hematol
and referenced in Journal of Genetic Syndromes & Gene Therapy